Drugmakers Extend Patent Lifespans Through Add-on Filings

VERA Brief

AI-generated. Grounded in the article and its cited sources.

Pharmaceutical companies are extending drug exclusivity periods by filing numerous add-on patents for minor modifications or new uses. This practice has extended the average patent duration, allowing companies to maintain higher prices and prevent generic competition.

Key facts

• Pharmaceutical manufacturers file add-on patents to extend market exclusivity for their drugs.
• These additional patents are often for minor modifications or new uses of existing drugs.
• The practice has increased the effective patent protection period beyond initial grants.
• Companies use this to maintain higher prices and prevent generic competition.
• The practice raises questions about balancing innovation incentives and affordable access to medications.